Weight loss drug Mounjaro debuts, rivals in hot pursuit

US company is pricing the anti-obesity treatment from ₹14,000 to ₹17,500 a month in India

- Jessica Jani

S drugmaker Eli Lilly & Co. brought its anti-obesity drug Mounjaro to India on Thursday, marking the country's first treatment of its kind, with monthly costs ranging from ₹14,000 to ₹17,500. The new drug, however, will face competition soon enough, with other foreign pharmaceutical companies planning to introduce similar products in a growing market.

Mounjaro's 2.5mg and 5mg vials will be priced at ₹3,500 and ₹4,375 respectively, in India. The injectable drug, used to treat obesity and type-2 diabetes, is to be taken once a week. The company had previously stated that it would price the drug, which costs around $1,000 per month ($86,315) in the US, competitively in India. "This India-specific pricing reflects Lilly's commitment to expanding access to innovative treatments in the country," the company said on Thursday.